Please Wait
Applying Filters...
menu
    • menu
    munit-sa-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Mebufotenin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GH Research Meets Primary Endpoint in Ph 2b Trial with GH001 in TRD
    GH Research Meets Primary Endpoint in Ph 2b Trial with GH001 in TRD

    03 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/03/3019385/0/en/GH-Research-Announces-Primary-Endpoint-Met-in-Phase-2b-Trial-with-GH001-in-TRD-Demonstrating-15-5-Point-Placebo-adjusted-MADRS-Reduction.html

    GLOBENEWSWIRE
    03 Feb 2025
    Share Share
    Beckley Psytech begins Phase IIa treatment resistant depression trial
    Beckley Psytech begins Phase IIa treatment resistant depression trial

    22 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/beckley-psytech-depression-trial/

    CLINICALTRIALSARENA
    22 Dec 2022
    Share Share
    Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003
    Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003

    21 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221221005221/en

    BUSINESSWIRE
    21 Dec 2022
    Share Share